Carvykti's success boosts Legend Biotech Corporation's Q4 2024 sales to $334M, solidifying market position. Click to find out ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales, outlines expansion strategies, and anticipates ...

Legend Biotech’s financial performance has been strong, with Carvykti sales showing significant growth. According to InvestingPro analysis, the company maintains a healthy financial position ...

The company’s flagship product, Carvykti, a CAR-T therapy for multiple myeloma, has demonstrated strong efficacy and is driving the company’s growth prospects. This comprehensive analysis examines ...

Q4 2024 Earnings Call Transcript March 11, 2025 Legend Biotech Corporation beats earnings expectations. Reported EPS is $0.08 ...

Legend Biotech’s (LEGN) shares have surged over 10% in the past few days, spurred by the company’s latest earnings report, thanks to ...